Risk acceleration by gout on major adverse cardiovascular events and all‐cause death in patients with diabetes and chronic kidney disease

Documenti analoghi

• EffiCacy and safety of ANagliptin when added to iNsulin and metformin therapy in patients with uncontrolled type 2 diAbetes ; randomized, placebo‐controlled, double‐blind, multicentre trial ( CANNA study)
  di: Ji Eun Jun, et al.
  Pubblicazione: (2025)
• Workplace‐based continuous glucose monitoring with structured education for pre‐diabetes and type 2 diabetes: A prospective community cohort study
  di: Ji‐Hee Ko, et al.
  Pubblicazione: (2025)
• Real world data showed that the dual GLP gip agonist, Tirzepatide is associated with lower mortality, cardiovascular events and adverse kidney events compared with GLP‐1 analogue
  di: Iskandar Idris
  Pubblicazione: (2024)
• Estimated glomerular filtration rate slope and risk of primary and secondary major adverse cardiovascular events and heart failure hospitalization in people with type 2 diabetes: An analysis of the EXSCEL trial
  di: Abderrahim Oulhaj, et al.
  Pubblicazione: (2024)
• Lobeglitazone improves glycaemic control as add‐on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double‐blind, randomised, placebo‐controlled trial
  di: Da Hea Seo, et al.
  Pubblicazione: (2025)